My Linh Kha

Senior Vice President and General Manager
Japan Asia-Pacific, Amgen

My Linh Kha is the senior vice president and general manager, Amgen Japan Asia Pacific China. My Linh has had more than 20 years of extensive international experience in both emerging and mature markets in the biopharmaceutical industry. Her expertise includes business start-ups, turnarounds and transformations. She has a deep knowledge of brand and organization strategy, healthcare regulatory policy and product pricing and a track record of delivering performances that exceed market expectations.
Prior to her current role, My Linh spent four years as vice president and general manager at Amgen Australia before assuming the same position at Amgen China. She joined Amgen Australia in 2011 as Business Unit Director for General Medicine before moving to the US as Executive Director of Marketing for Amgen’s Intercontinental Region, leading marketing for General Medicine across Latin America, Canada, Türkiye, the Middle East and Africa.
Before joining Amgen, My Linh spent more than a decade at Merck (MSD) taking various leadership roles of increasing responsibility, including Marketing lead (New Zealand), managing director (Vietnam), and head of Commercial Operations (Korea).
My Linh’s career started in the building and construction industry where she worked in business development and management consulting.
In 2020 My Linh was awarded a Shanghai Daily Women in Leadership award. She is a former member of the Australian Department of Industry, Innovation and Science Women’s Advisory Roundtable.
My Linh holds a Bachelor of Science degree and a Bachelor of Law degree from the University of Canterbury, New Zealand.
​

Speech title & Synopsis

Biotechnology Without Borders: Unlocking the Future Through Innovation and Collaboration

In this keynote, My Linh Kha, Senior Vice President and General Manager of Amgen’s JAPAC Region, will reflect on Amgen’s journey from a pioneer of the biotechnology era to a global leader in serious disease, anchored in bold science, a commitment to patients, and a deep belief in the power of innovation. She will explore how we are now at a defining moment where the convergence of biotech and technology is unlocking innovative opportunities to fight the world’s toughest diseases. Against this backdrop, she will highlight the urgent need for continued innovation and bold investment in biotechnology.
 
Asia plays a critical strategic role in Amgen’s global vision—fuelling scientific progress, shaping access models, and accelerating impact across borders. Taiwan exemplifies the region’s potential. Its research strength, digital momentum, and forward-leaning policy environment position is a key contributor to the future of precision medicine and biopharmaceutical advancement.
 
As the industry redefines what’s possible, Amgen remains deeply committed to Asia —and to helping shape a healthier, more connected future for patients around the world.